In an attempt to clarify the role of endogenous opioid peptides in substrate mobilization and hormonal responses to dynamic exercise, eight trained cyclists completed exercise trials at 90% of maximal O-2 consumption (VO2 max ) until exhaustion and at 70% VO2 max for 90 min. Trials were conducted after intravenous administration of the opiate antagonist naloxone (NAL, 0.1 mg/kg bolus + 0.1 mg.kg(-1).h(-1)) or volume-matched saline (SAL) at each intensity. Serum glucose was maintained at significantly higher levels at 60 and 90 min of exercise in the 70%-NAL than in the 70%-SAL trial and at all points during exercise and at 30 and 60 min of recovery in the 90%-NAL than in the 90%-SAL trial. The serum insulin response to exercise was not altered by NAL administration at either intensity. Serum C-peptide was similar to 50% higher at 60 and 90 min of exercise in the 70%-NAL than in the 70%-SAL trial but was significantly lower during exercise in the 90%-NAL than in the 90%-SAL trial. The plasma glucagon response to exercise at 70% VO2 max was not altered by NAL administration but was significantly elevated in the 90%-NAL vs. the 90%-SAL trial. Plasma epinephrine was 50-150% (similar to 2-3 nM) higher during exercise from 30 to 90 min of exercise in the 70%-NAL than in the 70%-SAL trial and was higher at termination (4.9 +/- 2.1 vs. 2.7 +/- 1.7 nM) in the 90%-NAL than in the 90%-SAL trial, although the difference in the 90% trial was not statistically significant. Plasma norepinephrine was significantly higher at 10 min of exercise (19.1 +/- 2.8 vs. 11.6 +/- 1.7 nM) and at termination (21.0 +/- 1.7 vs. 12.2 +/- 1.4 nM) in the 90%-NAL than in the 90%-SAL trial but was unaltered in the 70%-NAL vs. the 70%-SAL trial. Thus, opiate antagonism prevents the decline in serum glucose and potentiates the epinephrine response during prolonged exercise while augmenting the hyperglycemic response to high-intensity exercise, presumably via elevations in plasma catecholamines and glucagon.